methoxyamine has been researched along with Benign Neoplasms in 5 studies
methoxyamine: analytical reagent for aldehydes and ketones; strong irritant, can probably produce methemoglobinemia; RN given refers to parent cpd; structure
| Excerpt | Relevance | Reference |
|---|---|---|
| "TRC102 potentiates the activity of cancer therapies that induce base excision repair (BER) including antimetabolite and alkylating agents." | 2.78 | A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors. ( Adams, BJ; Anthony, SP; Figg, WD; Gerson, SL; Goldman, J; Gordon, MS; Leigh, BR; Liu, L; Mendelson, D; Ramanathan, RK; Rosen, LS; Spencer, S; Theuer, CP; Weiss, GJ; Xu, Y, 2013) |
| "Advanced cancer is a leading cause of death in the developed world." | 2.43 | DNA repair inhibition: a selective tumour targeting strategy. ( Hickson, ID; Madhusudan, S, 2005) |
| "Methoxyamine (MX) is a small molecule chemical inhibitor of BER that is shown to enhance chemotherapy and/or IR cytotoxicity in human cancers." | 1.39 | Developing an in silico model of the modulation of base excision repair using methoxyamine for more targeted cancer therapeutics. ( Avadhani, S; Gurkan-Cavusoglu, E; Kinsella, TJ; Liu, L; Loparo, KA, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gurkan-Cavusoglu, E | 1 |
| Avadhani, S | 1 |
| Liu, L | 3 |
| Kinsella, TJ | 2 |
| Loparo, KA | 1 |
| Yang, S | 1 |
| Savvides, P | 1 |
| Gerson, SL | 2 |
| Xu, Y | 2 |
| Gordon, MS | 1 |
| Rosen, LS | 1 |
| Mendelson, D | 1 |
| Ramanathan, RK | 1 |
| Goldman, J | 1 |
| Anthony, SP | 1 |
| Figg, WD | 1 |
| Spencer, S | 1 |
| Adams, BJ | 1 |
| Theuer, CP | 1 |
| Leigh, BR | 1 |
| Weiss, GJ | 1 |
| Madhusudan, S | 1 |
| Hickson, ID | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open Label Phase 1 Dose Finding Study of TRC102 in Combination With Pemetrexed in Patients With Advanced or Metastatic Solid Cancer for Whom Curative Therapy is Unavailable[NCT00692159] | Phase 1 | 28 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for methoxyamine and Benign Neoplasms
| Article | Year |
|---|---|
Coordination of DNA mismatch repair and base excision repair processing of chemotherapy and radiation damage for targeting resistant cancers.
Topics: DNA Damage; DNA Mismatch Repair; DNA Repair; Drug Resistance, Neoplasm; Genes, BRCA1; Genes, BRCA2; | 2009 |
DNA repair inhibition: a selective tumour targeting strategy.
Topics: Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; DNA Repair; DNA-Binding Proteins; Human | 2005 |
1 trial available for methoxyamine and Benign Neoplasms
| Article | Year |
|---|---|
A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2013 |
2 other studies available for methoxyamine and Benign Neoplasms
| Article | Year |
|---|---|
Developing an in silico model of the modulation of base excision repair using methoxyamine for more targeted cancer therapeutics.
Topics: Animals; Antineoplastic Agents; Computer Simulation; DNA Repair; DNA, Neoplasm; Drug Design; Drug Th | 2013 |
Development and validation of an LC-MS/MS method for pharmacokinetic study of methoxyamine in phase I clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzaldehydes; Chromatography, Liquid; Clinical Tria | 2012 |